Innovative Capital Solutions
for private companies & their shareholders
Times have changed.
Building private companies takes more effort, dedication and capital than ever before. And achieving company exits by trade sale or IPO takes more than double the time that it did a decade ago. As a result, founders, executives and investors face tremendous challenges maintaining a collective focus on corporate aspirations while also pursuing their own individual return objectives.
Second Alpha Partners can help. Second Alpha crafts innovative capital solutions that allow founders, managers and investors in private companies to achieve liquidity prior to company sales or IPOs. Second Alpha buys shares and convertible securities on a secondary basis.
Connect with us
Subcribe to our newsletter
Apis Growth Fund II invests US$50 million Series C in Giift, a Global Leader in Loyalty Program Management
Apis Growth Fund II, a private equity fund managed by Apis Partners LLP, a UK-based asset manager that supports growth stage financial services and financial infrastructure businesses, has invested US$50 million in Giift, the global leader in loyalty program management and development. Apis Growth Fund II was the sole investor in the Series C round.
“We are humbled to be acknowledged as a top leader by G2, a ranking from customers and users of our product, showcasing the value and power of Prove’s platform, innovation, and commitment as a leader in the digital identity space,” said Rodger Desai, Co-Founder and CEO of Prove. “Prove is on a mission to deliver digital trust, allowing businesses to garner the confidence to do more in the digital-first world that continues to evolve.
Genetics testing company 23andMe received Food and Drug Administration clearance for its prostate cancer risk test, the company announced today. It’s 23andMe’s third clearance for a cancer risk report — the company also has tests for genes that predict breast and colorectal cancer risk.